Drug reference

Bendroflumethiazide

Thiazide Diuretic · Diuretic

Also known as Bendrofluazide, NATURETIN

Thiazide DiureticDiuretic

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

incl. contraindicated

PREGNANCY

—

not curated

Top interactionssee all 12 →

QuinidineContraindicatedTextbookG&G 14e · p567
LithiumSevereTextbookG&G 14e · p378
Aminolevulinic AcidSevereDatabaseDDInter
AmiodaroneSevereDatabaseDDInter

Mechanism

The Na+-Cl– symporter (called ENCCl or TSC) is expressed predominantly in the kidney and is localized to the apical membrane of distal convoluted tubule (DCT) epithelial cells. Bendroflumethiazide, as a thiazide diuretic, inhibits this Na+-Cl– symporter in the DCT. This inhibition prevents the reabsorption of sodium and chloride, leading to increased excretion of water, sodium, and chloride, thus promoting diuresis.

Indications

OedemaHypertensionedema associated with diseases of the heart (CHF)edema associated with diseases of the liver (hepatic cirrhosis)edema associated with diseases of the kidney (nephrotic syndrome, chronic renal failure, acute glomerulonephritis)Ca2+ nephrolithiasisosteoporosisnephrogenic diabetes insipidusBr− intoxication

Dosing

Adult: Oedema: Initially 5–10 mg once daily or on alternate days in the morning; maintenance 5–10 mg 1–3 times a week. Hypertension: 2.5 mg daily in the morning, higher doses are rarely necessary.
Max dose: 10 mg daily

Pharmacokinetics

Half-life

~25 hours

Bioavailability

~100%

Metabolism

~70% metabolism

Excretion

~25% renal excretion of intact drug, ~75% unknown pathway of elimination

Contraindications

Addison’s disease
hypercalcaemia
hyponatraemia
refractory hypokalaemia
symptomatic hyperuricaemia
hypersensitive to sulfonamides

Side effects

Common

gastrointestinal disordergoutvertigoheadachephotosensitivityskin rasheserectile dysfunctionhypokalemiahyperuricemiadecreased glucose toleranceincreased plasma LDL cholesterolincreased plasma total cholesterolincreased plasma total triglycerides

Serious